Blood Bacterial 16S rRNA Gene Alterations in Women With Polycystic Ovary SyndromeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the blood bacterial microbiome of 24 women with polycystic ovary syndrome (PCOS) against 24 healthy controls. They used 16S rRNA gene sequencing to profile bacterial DNA circulating in blood, a compartment whose microbiome in PCOS had not previously been characterized.
How was it studied?
Blood bacterial DNA was sequenced on the MiSeq platform in this case control design. Alpha and beta diversity metrics compared within-group and between-group community differences, LEfSe identified taxa that best distinguished the groups, and KEGG functional prediction estimated pathway-level differences at the genus level.
What did they find?
Women with PCOS had significantly lower alpha diversity and a distinct beta diversity profile in blood microbiome compared to controls. Proteobacteria, Firmicutes, and Bacteroidetes decreased while Actinobacteria increased at the phylum level. LEfSe showed decreases in Burkholderiaceae, Lachnospiraceae, Bacteroidaceae, Ruminococcaceae, and S24-7, alongside increases in Nocardioidaceae and Oxalobacteraceae, and 14 KEGG pathways differed significantly between groups.
Why it matters
This is the first report of blood microbiome alterations in PCOS, extending prior gut dysbiosis findings to a new anatomical compartment. The distinct taxonomic and functional signature suggests blood bacterial DNA could serve as a novel biomarker axis for PCOS.